These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10933188)

  • 1. Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia.
    Westermann J; Kopp J; Körner I; Richter G; Qin Z; Blankenstein T; Dörken B; Pezzutto A
    Bone Marrow Transplant; 2000 May; 25 Suppl 2():S46-9. PubMed ID: 10933188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
    Westermann J; Kopp J; van Lessen A; Hecker AC; Baskaynak G; le Coutre P; Döhner K; Döhner H; Dörken B; Pezzutto A
    Br J Haematol; 2007 May; 137(4):297-306. PubMed ID: 17408402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.
    Boissel N; Rousselot P; Raffoux E; Cayuela JM; Soulier J; Mooney N; Charron D; Dombret H; Toubert A; Rea D
    J Leukoc Biol; 2006 Apr; 79(4):747-56. PubMed ID: 16461746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML.
    Litzow MR; Dietz AB; Bulur PA; Butler GW; Gastineau DA; Hoering A; Fink SR; Letendre L; Padley DJ; Paternoster SF; Tefferi A; Vuk-Pavlović S
    Cytotherapy; 2006; 8(3):290-8. PubMed ID: 16793737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia.
    Choudhury A; Gajewski JL; Liang JC; Popat U; Claxton DF; Kliche KO; Andreeff M; Champlin RE
    Blood; 1997 Feb; 89(4):1133-42. PubMed ID: 9028934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
    He L; Feng H; Raymond A; Kreeger M; Zeng Y; Graner M; Whitesell L; Katsanis E
    Cancer Immunol Immunother; 2001 Mar; 50(1):31-40. PubMed ID: 11315508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells.
    Dietz AB; Bulur PA; Erickson MR; Wettstein PJ; Litzow MR; Wyatt WA; Dewald GW; Tefferi A; Pankratz VS; Vuk-Pavlović S
    J Hematother Stem Cell Res; 2000 Feb; 9(1):95-101. PubMed ID: 10738977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
    Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
    J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-alpha.
    Wang C; Al-Omar HM; Radvanyi L; Banerjee A; Bouman D; Squire J; Messner HA
    Exp Hematol; 1999 Jul; 27(7):1176-84. PubMed ID: 10390193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients.
    Osman Y; Takahashi M; Zheng Z; Koike T; Toba K; Liu A; Furukawa T; Aoki S; Aizawa Y
    Leukemia; 1999 Feb; 13(2):166-74. PubMed ID: 10025889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation.
    Orsini E; Calabrese E; Maggio R; Pasquale A; Nanni M; Trasarti S; Tafuri A; Guarini A; Foa R
    Leuk Res; 2006 Jul; 30(7):785-94. PubMed ID: 16527350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response.
    Eibl B; Ebner S; Duba C; Böck G; Romani N; Erdel M; Gächter A; Niederwieser D; Schuler G
    Genes Chromosomes Cancer; 1997 Nov; 20(3):215-23. PubMed ID: 9365828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.
    Sun JY; Krouse RS; Forman SJ; Senitzer D; Sniecinski I; Chatterjee S; Wong KK
    Cancer Res; 2002 Jun; 62(11):3175-83. PubMed ID: 12036931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
    Babatz J; Röllig C; Oelschlägel U; Zhao S; Ehninger G; Schmitz M; Bornhäuser M
    J Hematother Stem Cell Res; 2003 Oct; 12(5):515-23. PubMed ID: 14594508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
    Sun JY; Senitzer D; Forman SJ; Chatterjee S; Wong KK
    Cancer Immunol Immunother; 2003 Dec; 52(12):761-70. PubMed ID: 14564482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation.
    Fujii S; Shimizu K; Fujimoto K; Kiyokawa T; Shimomura T; Kinoshita M; Kawano F
    Jpn J Cancer Res; 1999 Oct; 90(10):1117-29. PubMed ID: 10595741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum-free culture of dendritic cells from patients with chronic myeloid leukemia in vitro and estimation of their cytotoxicity.
    Zhao W; Xing P; Wei X; Wang T; Yang D; Li M
    Chin Med J (Engl); 2002 Sep; 115(9):1296-300. PubMed ID: 12411098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Construction of genetically modified dendritic cell vaccine expressing bcr/abl fusion gene and inducing specific cytotoxic T lymphocytes to kill K562 cells in vitro].
    Wang WW; Huang RW; Hu Y; Li XD; Wang DN; He Y; Liu JJ
    Ai Zheng; 2009 Jun; 28(6):602-6. PubMed ID: 19635197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
    Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
    Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
    Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.